After Elections, Germany’s Pharma Industry Faces Uncertain Future
This article was originally published in The Pink Sheet Daily
Executive Summary
German elections have led to the possibility of several coalition government constellations, but none are particularly good for the pharmaceutical industry.
You may also be interested in...
European Notebook: CHMP Opens Up A Bit; France Looks For $1B In Price Cuts; Spain Making Good On Pharma Debts
Europe's top scientific advisory panel, the CHMP, could reveal more of its thoughts on product approvals next year. French biopharma tries to stave off deep cuts in budgetary debate; Germany may consider more health reforms following recent elections; Invesco, Servier see exec changes
German Austerity Measures Continue As Firms Dispute How Much Has Already Been Saved
Despite overall economic growth, the German health ministry refuses to lift the pharmaceutical price freeze or obligatory rebate to health insurers, saying industry is coping well with them; firms say they have already sacrificed more than had initially been asked.
Success Of German Cost-Control Law Raises Prospect Of Further Cuts For Pharma
Germany's 2011 pharmaceutical prescribing report shows that the cost control law (AMNOG) is fulfilling its purpose, prompting insurers to call for even further pressure on the industry to reduce costs.